News Channels

06 Jan 2022 POLARISqb and PhoreMost announce a multi-target collaboration to investigate next-generation cancer therapies
06 Jan 2022 Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator
06 Jan 2022 FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate
06 Jan 2022 Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases
06 Jan 2022 Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
05 Jan 2022 Rain Therapeutics and Roche to Collaborate on Clinical Trial of Milademetan Combination with Anti-PD-L1 Immunotherapy for Various Solid Tumor Indications
05 Jan 2022 Leiden University Medical Center and Intravacc to Start Clinical Trial with New Intranasal Corona Vaccine
05 Jan 2022 Allena Pharmaceuticals Provides Clinical and Corporate Update
05 Jan 2022 Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study (CORAL-BOOST) Evaluating a T Cell-Enhanced Self-Amplifying mRNA (samRNA) Vaccine Against COVID-19
05 Jan 2022 Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration
05 Jan 2022 Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008
05 Jan 2022 Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data
05 Jan 2022 Dystrogen Therapeutics Announces First in Man Dosing of Novel Chimeric Cell Therapy for Duchenne Muscular Dystrophy and Reports 6-week Clinical Outcomes
05 Jan 2022 AVROBIO Reprioritizes Pipeline Programs
05 Jan 2022 Amylyx Pharmaceuticals Submits Marketing Authorization Application (MAA) for AMX0035 for the Treatment of ALS
05 Jan 2022 Verseau Therapeutics Announces FDA Clearance of Investigational New Drug Application for VTX-0811, a PSGL-1 Monoclonal Antibody
05 Jan 2022 NewAmsterdam Pharma Doses First Patient in Phase 3 BROADWAY Trial of Obicetrapib in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) and/or Established Atherosclerotic Cardiovascular Disease (ASCVD)
05 Jan 2022 OrphoMed, Inc. Announces Positive Phase 2 Results for ORP-101 100 mg Once-Daily Dose in IBS-D Patients
05 Jan 2022 Genmab and Synaffix Enter into License Agreement for ADC Technology
05 Jan 2022 AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up